Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD induction followed by risk-adapted transplant and lenalidomide maintenance in newly diagnosed multiple myeloma
2008-000007-28Phase 2Completed
- Sponsor
- University Hospital Würzburg
- Start
- Feb 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, doxorubicin and dexamethasone in multiple myeloma (MM), sponsored by University Hospital Würzburg. Primary endpoint: Response rate at start of scheduled lenalidomide maintenance. Started Feb 2009; status: completed.
02
Drugs
lenalidomidedoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-000007-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000007-28.